Mutual of America Capital Management LLC Sells 8,657 Shares of Gilead Sciences, Inc. $GILD

Mutual of America Capital Management LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,631 shares of the biopharmaceutical company’s stock after selling 8,657 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $17,275,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in GILD. Rothschild Investment LLC boosted its holdings in Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares in the last quarter. Hemington Wealth Management raised its position in shares of Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 85 shares during the period. Ignite Planners LLC lifted its holdings in shares of Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares in the last quarter. Archer Investment Corp grew its position in Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after purchasing an additional 87 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Gilead Sciences by 0.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock valued at $3,912,000 after purchasing an additional 87 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Wolfe Research reiterated an “outperform” rating and set a $150.00 price target on shares of Gilead Sciences in a research note on Monday, December 15th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $133.52.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the sale, the chief financial officer owned 153,503 shares in the company, valued at $18,727,366. The trade was a 1.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 141,757 shares of company stock worth $17,569,112 in the last three months. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 3.7%

GILD stock opened at $135.93 on Monday. Gilead Sciences, Inc. has a 1-year low of $92.26 and a 1-year high of $136.30. The stock has a market cap of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The stock’s fifty day simple moving average is $123.98 and its two-hundred day simple moving average is $118.71. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.